Welcome to The Ammon-Pinizzotto Center for Women’s Mental Health at MGH. Our Center, established in 1989, has been renamed following the generous gift from Carol Ammon and Dr. Marie Pinizzotto. These resources will be used to realize the overarching mission of the Center.
This website provides a range of current information including discussion of new research findings in women’s mental health and how such investigations inform day-to-day clinical practice. Despite the growing number of studies being conducted in women’s health, the clinical implications of such work are frequently controversial, leaving patients with questions regarding the most appropriate path to follow. Providing these resources to patients and their doctors so that individual clinical decisions can be made in a thoughtful and collaborative fashion dovetails with the mission of our Center.
All pregnant women ages 18-45 are eligible to enroll in the registry. The primary goal of this Registry is to determine the frequency of major malformations, such as heart defects, cleft lip, or neural tube defects, in infants exposed to atypical antipsychotics and antidepressants during pregnancy. We are currently seeking both controls and those being treated with atypical antipsychotics and/ or antidepressants. For more information, please visit this page, call 1-866-961-2388 or e-mail firstname.lastname@example.org.
Hummingbird Study: A new medication treatment study for postpartum depression
Anxious. Sad. Crying a lot. These are symptoms of postpartum depression. The Hummingbird Study is a research study evaluating an investigational medication in women suffering from moderate to severe postpartum depression.
You may qualify to participate in this study if you are between 18 to 45 years old, gave birth within the last 6 months, and feel extremely sad, anxious, or overwhelmed frequently as these symptoms are associated with postpartum depression.
If you qualify and decide to participate, you will receive 24-hour care and support for your postpartum depression during the 3-day, in-patient period. All study-related medical care and medication provided at no cost.
Course of ADHD in Pregnancy and the Postpartum
If you are less than 20 weeks pregnant and have a history of ADHD, you may be eligible to take part in an observational research study for women maintaining, decreasing, or discontinuing psychostimulants during pregnancy and the postpartum. Women who participate will have 6 study visits from time of enrollment (<20 weeks pregnant) to 24 weeks postpartum. The first visit must be in-person at Massachusetts General Hospital with the option to complete the remaining visits in-person or over the phone.
For more information, please call (617)726-2912 or email the study coordinator at email@example.com
Are you pregnant or planning a pregnancy? Do you feel depressed or have a history of depression? If you are less than 28 weeks pregnant or trying to conceive and have experienced depression now or in the past, you may be eligible to take part in a research study for the treatment of depression with a prenatal supplement. For more information, please visit this page, call Gina at 617-643-9284 or e-mail firstname.lastname@example.org.
Are you pregnant or planning to become pregnant? Do you have a history of depression? Do you want to lose weight or have a healthier lifestyle? You may be eligible to participate in a research study evaluating a new lifestyle intervention for weight loss. Participants will receive 10 sessions of therapy at no cost to you.
If you are interested in participating or would like additional information, please call Samantha at 617-643-2076.
The MGH Center for Women’s Mental Health
Perinatal and Reproductive Psychiatry Program
Simches Research Building
185 Cambridge St Suite 2200
Boston, MA 02114
To make an appointment:
Massachusetts General Hospital Clinical Program: (617) 724-7792
Location of appointments:
Wang Ambulatory Care Center, Massachusetts General Hospital
15 Parkman St., Floor 8
Boston, MA 02114-3117
August 23, 2017
We are excited to announce the enrollment of our 1000th participant in the National Pregnancy Registry for Atypical Antipsychotics! Formed in 2008, the Registry was established at MGH to prospectively evaluate the rates of malformations among infants exposed in utero to atypical antipsychotics. Data from the Registry thus far suggest that atypical antipsychotics as a class ...Read more
August 21, 2017
The use of the newer “atypical” or second-generation antipsychotic agents is increasing. Atypical antipsychotics are now used to treat a spectrum of psychiatric disorders, including schizophrenia, bipolar disorder, major depression, PTSD and other anxiety disorders. Using data from the Medicaid Analytic eXtract (MAX) data of pregnant women who delivered infants born between 2001 and 2010, ...Read more
August 17, 2017
In the United States, the prevalence of smoking in pregnant women has declined; however, according to data gathered from 29 states by the Pregnancy Risk Assessment Monitoring System (PRAMS), about 13% of women smoked during the last 3 months of pregnancy. The prevalence varied according to state, with the highest rates reported in West Virginia ...Read more
August 16, 2017
About 1.4 million people in the U.S. have been diagnosed with ADHD, and about 60-80% of children diagnosed with ADHD will need to take their medication into adulthood. When girls diagnosed in childhood become reproductive-aged women, they face challenging decisions regarding how to proceed with their treatment when they are also family planning. There are different ...Read more
Prescribing Psychotropic Medications with Opioids During Pregnancy May Increase Risk for Neonatal Withdrawal
August 9, 2017
Illicit opioid use has steadily increased over the past decade, and this increase is most prominent in the 18–25 age group, which includes women of reproductive age (Substance Abuse and Mental Health Services Administration, 2013). Paralleling this increase in illicit opiate use in this population has been a significant increase in the use of prescription ...Read more
August 7, 2017
There have long been concerns regarding the safety of the anticonvulsant valproate (Depakote) during pregnancy. Back in 2009, the American Academy of Neurology and American Epilepsy Society recommended against the use of valproic acid in women of childbearing age because of the various risks associated with prenatal exposure. Raising similar concerns in 2014, the European ...Read more